Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson's Disease

Core Viewpoint - Serina Therapeutics has secured an agreement for up to $20 million in financing to advance its lead candidate SER-252 for advanced Parkinson's disease, with the potential for additional funds through warrants [1][2][4]. Financing Details - The financing consists of an unsecured convertible note issued in five tranches, tied to clinical and operational milestones [2][7]. - Each tranche drawn carries 100% warrant coverage, with warrants priced at $5.44, which is 105% of the closing stock price on September 8, 2025 [3][7]. - The financing structure allows for capital deployment in alignment with trial progress, maintaining flexibility for additional funding [2][4]. Clinical Development Plans - Serina plans to submit a U.S. IND application in Q4 2025, incorporating FDA recommendations, and begin patient dosing in Australia in the same quarter [5]. - Following U.S. IND clearance, enrollment in the U.S. is anticipated to start in Q1 2026 [5]. - The SER-252-1b study is a randomized, double-blind, placebo-controlled Phase 1b trial designed to evaluate safety, tolerability, and pharmacokinetics [6][8]. Product Overview - SER-252 is an investigational apomorphine therapy designed for continuous dopaminergic stimulation via subcutaneous injection, aimed at reducing motor fluctuations in advanced Parkinson's patients [9]. - The therapy leverages the enFuse™ wearable drug delivery platform to enhance patient comfort and convenience [9]. - Serina's proprietary POZ Platform™ technology aims to improve drug delivery and stability, potentially applicable across various therapeutic areas [10][11].